Educational inequalities in statin treatment for preventing cardiovascular disease: cross-sectional analysis of UK Biobank

Short title: Educational inequalities in statin treatment

Alice R Carter[1,2*], Dipender Gill[3-7], Richard Morris[2,8], George Davey Smith[1,2,9], Amy E Taylor[2,9], Neil M Davies[1,2,10†], Laura D Howe[1,2†]

1) MRC Integrative Epidemiology Unit, University of Bristol Population Health Sciences, Bristol Medical School, University of Bristol
2)
3) Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
4) Centre for Pharmacology & Therapeutics, Department of Medicine, Hammersmith Campus, Imperial College London, London, UK.
5) Novo Nordisk Research Centre Oxford, Old Road Campus, Oxford, UK
6) Clinical Pharmacology and Therapeutics Section, Institute of Medical and Biomedical Education and Institute for Infection and Immunity, St George's, University of London, London, UK
7) Clinical Pharmacology Group, Pharmacy and Medicines Directorate, St George's University Hospitals NHS Foundation Trust, London, UK
8) Centre for Academic Primary Care, University of Bristol
9) NIHR Bristol Biomedical Research Centre, University of Bristol
10) K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, NTNU, Norwegian University of Science and Technology, Norway.

[†]NMD and LDH contributed equally

Corresponding author:

Ms Alice R Carter

Oakfield House,

Oakfield Grove,

Bristol,

BS8 2BN

alice.carter@bristol.ac.uk

@alicerosecarter

Funding

No funding body has influenced data collection, analysis or its interpretations. This research was conducted using the UK Biobank Resource using application 10953. ARC is funded by the UK Medical Research Council Integrative Epidemiology Unit, University of Bristol (MC_UU_00011/1). ARC, GDS, AET, NMD and LDH work in a unit that receives core funding from the UK Medical Research Council and University of Bristol (MC_UU_00011/1). DG is supported by the Wellcome Trust 4i Programme (203928/Z/16/Z) and British Heart Foundation Centre of Research Excellence (RE/18/4/34215) at Imperial College London. AET and GDS are supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at University Hospitals Bristol NHS Foundation and the University of Bristol. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. The Economics and Social Research Council support NMD via a Future Research Leaders grant (ES/N000757/1) and a Norwegian Research Council Grant number 295989. LDH is funded by a Career Development Award from the UK Medical Research Council (MR/M020894/1).

Disclosures

DG is employed part-time by Novo Nordisk. The remaining authors have no conflicts of interest to declare.

Contributions:

ARC designed the study, cleaned and analysed the data, interpreted the results, wrote and revised the manuscript. DG advised on defining medications, interpreted the results and critically reviewed and revised the manuscript. RM advised on analyses, interpreted the results and critically reviewed and revised the manuscript. GDS, AET, NMD and LDH all designed the study, interpreted the results, critically reviewed and revised the manuscript and provided supervision for the project. NMD and LDH contributed equally and are joint senior authors on this manuscript. ARC and LDH serve as

guarantors of the paper. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Transparency statement:

ARC affirms that the manuscript is an honest, accurate and transparent account of the study being reported and no important aspects of the study have been omitted.

Acknowledgements:

This work was carried out using the computational facilities of the Advanced Computing Research Centre - http://www.bris.ac.uk/acrc/ and the Research Data Storage Facility of the University of Bristol - http://www.bris.ac.uk/acrc/storage/.

Word count: 4891

Abstract

Background: The most socioeconomically deprived individuals remain at the greatest risk of cardiovascular disease. Differences in risk adjusted use of statins between educational groups may contribute to these inequalities. We explore whether people with lower levels of educational attainment are less likely to take statins for a given level of cardiovascular risk.

Methods and findings: Using data from a large prospective cohort study, UK Biobank, we calculated a QRISK3 cardiovascular risk score for 472 097 eligible participants with complete data on self-reported educational attainment and statin use (55% female; mean age, 56). We used logistic regression to explore the association between i) QRISK3 score and self-report statin use and ii) educational attainment and self-report statin use. We then stratified the association of QRISK3 score, and statin use by strata of educational attainment to test for an interaction. In this sample, greater education was associated with lower statin use, whilst higher cardiovascular risk (assessed by QRISK3 score) was associated with higher statin use in both females and males. There was evidence of an interaction between QRISK3 and education, such that for the same QRISK3 score, people with more education were more likely to report taking statins. For example, in women with 7 years of schooling, equivalent to leaving school with no formal qualifications, a one unit increase in QRISK3 score was associated with a 7% higher odds of statin use (odds ratio (OR) 1.07, 95% CI 1.07, 1.07). In contrast, in women with 20 years of schooling, equivalent to obtaining a degree, a one unit increase in QRISK3 score was associated with an 14% higher odds of statin use (OR 1.14, 95% CI 1.14, 1.15). Comparable ORs in men were 1.04 (95% CI 1.04, 1.05) for men with 7 years of schooling and 1.08 (95% CI 1.08, 1.08) for men with 20 years of schooling. Linkage between UK biobank and primary care data meant we were able to carry out a number of sensitivity analyses to test the robustness of our findings. However, a limitation of our study is that a number of assumptions were made when deriving QRISK3 scores which may overestimate the scores.

Conclusions: For the same level of cardiovascular risk, individuals with lower educational attainment are less likely to receive statins, likely contributing to health inequalities.

Keywords: Inequalities, cardiovascular disease, statins, education, QRISK

Summary

What is already known on this topic?

- Despite reductions in the rates of cardiovascular disease in high income countries, individuals who are the most socioeconomically deprived remain at the highest risk.
- Although intermediate lifestyle and behavioural risk factors explain some of this, much of the effect remains unexplained.

What does this study add?

- For the same increase in QRISK3 score, the likelihood of statin use increased more in individuals with high educational attainment compared with individuals with lower educational attainment.
- These results were similar when using UK Biobank to derive QRISK3 scores and when using QRISK scores recorded in primary care records, and when using self-reported statin prescription data or prescription data from linked primary care records.
- The mechanisms leading to these differences are unknown, but both health seeking behaviours and clinical factors may contribute.

Introduction

Despite reductions in cardiovascular morbidity and mortality in high income countries, the most socioeconomically deprived groups remain at the highest risk of cardiovascular disease (CVD) (1, 2). There is evidence that education is a causal risk factor for CVD (3-5). We have previously demonstrated that part of this association acts through three modifiable risk factors; body mass index (BMI), systolic blood pressure and lifetime smoking behaviour (5). However, as much as 60% of the effect of education on CVD remains unexplained.

Previous studies have assessed the association of socioeconomic position (SEP) with primary (prescribed prior to a cardiovascular event) and secondary (prescribed as a result of a cardiovascular event) CVD preventative treatment rates; however, the direction of effect has been mixed (6-10). In an analysis of the Whitehall II cohort study (11), and in the British Regional Heart Study (12) there was no evidence of socioeconomic differences in statin prescribing. In other studies it has been reported that those with lower socioeconomic position are more likely to be prescribed statins (6, 8, 13, 14). Conversely, some studies have found that individuals of lower socioeconomic position are less likely to be prescribed statins (9, 10, 15, 16).

One key challenge in trying to unpick the role of education in statin prescribing (or other primary or secondary prevention mechanisms) is that lower education is associated with higher levels of cardiovascular risk factors. For example, lower education is associated with higher BMI, smoking, higher blood pressure, and lower levels of physical activity (5, 17, 18). Therefore, individuals with low education likely have a greater underlying risk of CVD and therefore potentially have a greater need for statins. However, it is possible that educational differences in health-seeking behaviour or interactions between patients and healthcare professionals may result in those with higher educational levels being prescribed preventative medication at a lower level of clinical ‘need’ (19, 20). Consequently, it is more informative to test whether there are educational differences in statin

use dependent upon cardiovascular risk, rather than to look at the crude association of education and statin use.

Using the UK Biobank cohort, we investigated whether for a given level of cardiovascular risk, measured using the QRISK3 cardiovascular risk score, people with lower education were less likely to report taking statins as primary prevention than those with higher education (21-23). In secondary analyses we identify whether there are inequalities in the type of statin (Atorvastatin compared with Simvastatin) prescribed, given that Atorvastatin has greater efficacy than Simvastatin but is more costly (24-27).

Methods

UK Biobank

The UK Biobank study recruited 503 317 UK adults between 2006 and 2010. Participants attended baseline assessment centres involving questionnaires, interviews, anthropometric, physical and genetic measurements (15, 16). All UK Biobank participants are linked to hospital episode statistic (HES) data, with data available from 1997 in England, 1998 in Wales and 1981 in Scotland (28), with the most recent entry recorded in this analysis in May 2017. Additionally, a subset of participants (approximately 230,000 participants) are linked with primary care data and prescribing data (29). In this analysis, we use data from baseline assessment centres, HES data, and linked primary care data where available.

QRISK risk score

We created a risk score for cardiovascular disease using the QRISK3 algorithm (23). The QRISK3 score is currently used in primary care systems in England and Wales to define the treatment threshold for statin prescriptions. Current guidelines recommend prescribing statins to individuals with a 10% or greater risk of having a cardiovascular event within 10 years (30, 31). QRISK3 scores were derived for all participants with complete data for educational attainment and reported statin use (N= 472 097)

159 (Supplementary Figure 1). For individuals with missing data in any of the QRISK3 variables multiple
160 imputation was used (see statistical analysis section). Scores were derived according to the publicly
161 available QRISK3 algorithm https://qrisk.org/three/index.php.

162 Where measures were recorded in baseline assessment centres, such as BMI, Townsend deprivation
163 score or systolic blood pressure, these values were used. With the exception of systolic blood
164 pressure variability (standard deviation of repeated values) and coronary heart disease in a first-
165 degree relative under 60 years of age, all QRISK3 variables were available in UK Biobank. In the
166 absence of repeated measures of systolic blood pressure on UK biobank a measure of systolic blood
167 pressure variability was derived from the standard deviation of the two recorded measurements of
168 systolic blood pressure at the baseline assessment centre. A measure of family history of CVD was
169 ascertained from reported heart disease in mothers, fathers and siblings of UK Biobank participants,
170 however age of diagnosis and subtype of CVD, could not be determined.

171 Full details of all variable measurements are available in the supplementary materials. All variables
172 used and assumptions made when deriving QRISK3 scores are available in Supplementary Table 1.
173 UK Biobank treatment codes used to identify cases and ICD9, ICD10 codes and are presented in
174 Supplementary Tables 2 and 3.

175 In a subset of individuals with linked primary care data, QRISK (read 2 code: 38DF.) (N=1 495) (21), or
176 QRISK2 scores (read 2 code: 39DP.) (N = 10 633) (22) were recorded from 2007 onwards. Where
177 more than one QRISK score was recorded for an individual, the first recorded value was used in
178 analysis.

179 Measuring educational attainment

180 UK Biobank participants reported their highest qualification achieved at baseline assessment
181 centres, which was converted to the International Standard Classification for Education (ISCED)
182 coding of years of education (Supplementary Table 4) (32).

183 ## Measuring statin use

184 Participants were asked about regular medication they were taking, details of which were recorded
185 by UK Biobank study nurses. From this, a primary variable for any reported statin use was generated.
186 The type of statin used (Atorvastatin, Simvastatin, Fluvastatin, Pravastatin and Rosuvastatin) was
187 recorded by study nurses and was used to derive a variable for type of statin.

188 In individuals with linked primary care data, statin prescriptions were recorded in prescription data.
189 In these individuals, a measure of validated statin use was created, defined by a prescription in both
190 the 3 months before and 3 months after baseline. For sensitivity analyses in individuals with a QRISK
191 or QRISK2 score recorded in primary care data, statin use was defined as any statin prescription after
192 a QRISK score was recorded.

193 ## Exclusion criteria

194 Prevalent CVD cases at baseline, who would receive a statin prescription according to NICE
195 guidelines (30, 31, 33, 34), were excluded from analyses. These cardiovascular diagnoses and events
196 were ascertained through linkage to HES data, with cases defined according to ICD-9 and ICD-10
197 codes (Supplementary Table 3). Individuals were excluded if they had experienced at least one
198 diagnosis of myocardial infarction, angina, stroke, transient ischaemic attack, peripheral arterial
199 disease, type 1 diabetes, chronic kidney disease or familial hypercholesterolaemia (30, 34). The date
200 for each diagnosis is provided in the HES data, which was linked with the date of assessment centre
201 visit provided by UK Biobank.

202 Complete case analyses were carried out on 368 721 individuals, with complete data on age, sex,
203 educational attainment, self-reported statin (medication) use and all variables required for the
204 QRISK3 score (Supplementary Table 1 and Supplementary Figure 1).

Code and data availability

The derived variables have been returned to UK Biobank for archiving. The code used to derive QRISK3 scores and carry out analyses is available at github.com/alicerosecarter/statin_inequalities.

Patient and public involvement

Ethical approval for this study was sought from the UK Biobank (project 10953). No patients or participants were involved in setting the research question or the outcome measures, nor were they involved in developing plans for design or implementation of the study. No patients were asked to advise on the interpretation or writing up of results.

Statistical analyses

To maximise power and potentially reduce bias, multivariable multiple imputation by chained equations (35) was used to impute variables included in the QRISK3 score with missing data, under the missing at random assumption. The sample for imputation was defined as all individuals with complete data on educational attainment and reported statin use. The proportion of missing data ranged from 0% to 15% (see Supplementary Table 5 for full details). In total, 77% of participants had no missing data, 13% of participants were missing data for one QRISK3 variable, 8% of participants were missing data for two QRISK3 variables and 2% of participants were missing data for three, four or five variables. A total of 25 imputed datasets were generated (36). Imputation was carried out separately within strata of years of education and sex to preserve interactions tested in the statistical analyses (37). The mean and standard deviation of continuous variables or proportion and standard error of categorical variables in the imputed data were compared with those from the complete data. All analyses were then carried out in each imputed dataset, with results combined according to Rubin's rules.

227 It was determined *a priori* to carry out all analyses stratified by sex given the known differences in
228 cardiovascular risk profiles for males and females (38, 39), as well as the QRISK3 score being derived
229 separately by sex (23).

230 To confirm the validity of the derived QRISK3 score, a univariable logistic regression model was used
231 to assess the association of the risk score with i) self-reported statin use and ii) incident CVD.

232 We estimated the associations of years of education with i) QRISK3 score (using linear regression)
233 and ii) statin use (using logistic regression).

234 *Testing for interaction between QRISK3 score and educational attainment on statin use*

235 Logistic regression was used to estimate the association of QRISK3 score with self-reported statin
236 use, stratified by years of education, providing an estimate of interaction on the multiplicative scale
237 (sFigure 2, Route 1). These analyses were not adjusted for any other covariates, assuming all
238 relevant variables are incorporated into the QRISK3 score. Evidence of an interaction between
239 QRISK3 score and years of education was evaluated in a linear model where the interaction term
240 QRISK3×educational attainment was included in the regression model.

241 *Secondary analyses*

242 To test the hypothesis that there may be educational inequalities in the type of statin prescribed, in
243 individuals who reported using statins to baseline study nurses, we assessed i) whether there was an
244 association of QRISK3 score and years of education independently with self-reported Atorvastatin,
245 which has been suggested to have a greater efficacy, compared with self-reported Simvastatin
246 (baseline) (24-26) and ii) whether there was any evidence of an interaction between QRISK3 score
247 and years of education on type of statin prescribed (sFigure 2, Route 2).

248 Analyses testing the association between QRISK3 and years of education on statin use and statin
249 type independently, as well as for any interaction between QRISK3 score and educational

250 attainment, on statin use and type of statin prescribed were replicated using complete case data
251 (sFigure 2, Route 3 and 4).

252 To test whether the self-reported statin use data affected the results, we repeated our analysis with
253 statin use defined as a prescription both 3 months before and after baseline from linked primary
254 care prescription data (sFigure 2, Route 5), and also repeated our main analysis with self-reported
255 statin use in the subset of participants with the linked prescription data (sFigure 2, Route 6).

256 In the subsample of primary care individuals with a QRISK or QRISK2 score recorded, analyses were
257 replicated to test for evidence of an interaction between QRISK score and incident statin prescribing.
258 This was defined as any prescription for a statin recorded in primary care data, excluding individuals
259 who reported using statins to study nurses at the baseline assessment centre (sFigure 2, Route 7).
260 QRISK scores were included if they were recorded on or prior to the date of first statin prescription,
261 but consideration was not given to the time between both events.

262 Two further estimates of QRISK3 were derived excluding i) variability of systolic blood pressure and
263 ii) family history of cardiovascular disease from QRISK3 scores. The pairwise correlation between
264 scores with and without these variables was tested.

265 Results

266 UK Biobank sample

267 In the main analyses (N = 472 097) 55% of participants were female with a mean age of 56. In
268 females, the QRISK3 score implied a mean 10-year risk of a cardiovascular event of 6.9% (standard
269 deviation (SD) = 5.5). In males, the QRISK3 score implied mean a 10-year risk of a cardiovascular
270 even of 13.1% (SD = 8.4). Participants were more likely to have completed 20 years of education
271 (female = 35%, male = 38%) than 7 years of education (female = 14%, male = 14%). 10% of females
272 and 17% of males reported using statins.

273 The distribution of variables was similar between the multiply imputed dataset, complete case data,

274 and in the subset of participants with linked primary care data (Supplementary Table 6).

275 Association of QRISK3 score with statins and cardiovascular disease

276 For a one unit increase in QRISK3 score (i.e. a 1% increase in the 10-year risk of experiencing a

277 cardiovascular event) in females, the odds ratio (OR) for reporting statin use to study nurses was

278 1.12 (95% confidence interval (CI): 1.12 to 1.13) and the OR for an incident cardiovascular event was

279 1.12 (95% CI: 1.12 to 1.12) (Figure 1 and Supplementary Table 7). Females with a QRISK3 score of 10

280 or greater were 1.34 (95% CI: 1.31 to 1.36) times more likely to report using statins than those with a

281 QRISK score of less than 10. In males, the OR for statin use was 1.07 (95% CI: 1.07 to 1.07) and for an

282 incident cardiovascular event the OR was 1.08 (95% CI: 1.08 to 1.08) per unit higher QRISK3 score

283 (Figure 1 and Supplementary Table 7). Males with a QRISK3 score of 10 or greater were 1.49 (95% CI:

284 1.46 to 1.52) times more likely to report using statins than those with a QRISK score of less than 10.

285 Figure 1: Odds of self-report statin use per unit increase in baseline QRISK3 score with no education

286 interaction and stratified by years of education in females and males



287

Analyses stratified by years of education provide an estimate of interaction on the multiplicative scale

P value for interaction in females = <0.001 and males = <0.001

Association of education with QRISK3 score and statin prescribing

Per year increase in educational attainment was associated with a -0.30 (95% CI: -0.30 to -0.29) reduction in mean QRISK3 score in females and a -0.35 (95% CI: -0.35 to -0.34) reduction in mean QRISK3 score in males (Supplementary Table 8 and Supplementary Figure 3).

The prevalence of statin use was highest in those in the lowest strata of educational attainment (equivalent to leaving school after 7 years, with no formal qualifications) (Supplementary Figure 4). Not accounting for cardiovascular risk, each additional year of education was associated with a lower odds of being prescribed statins (all types), (OR in females: 0.93; 95% CI: 0.93 to 0.93, OR in males: 0.96; 95% CI: 0.96 to 0.96) (Supplementary Table 7 and Supplementary Figure 5).

Interaction between education and QRISK3 score in relation to statin prescribing

In both females and males, there was evidence of an interaction between QRISK3 score and years of education on statin use, such that for the same increase in QRISK3 score, the likelihood of statin use increased more for those of high educational attainment. In females, per unit increase in QRISK3, the OR for reporting statin use in those with the greatest years of education (20 years, equivalent to obtaining a degree) was 1.14 (95% CI: 1.14 to 1.15) compared with an OR of 1.07 (95% CI: 1.07 to 1.07) for those with the least years of education (7 years, equivalent to leaving school with no formal qualifications) (Figure 1). In males, the OR for statin use per unit increase in QRISK3 score in those with 20 years of education was 1.08 (95% CI: 1.08 to 1.08) compared with an OR of 1.04 (95% CI: 1.04 to 1.05) for those with 7 years of education (Figure 1). For both females and males, the P value for interaction was <0.001.

Secondary analyses

Among individuals prescribed with either atorvastatin or simvastatin, those with higher QRISK3 scores were more likely to have been prescribed the more effective Atorvastatin. The OR for a one-unit higher QRISK3 and reporting Atorvastatin use was, OR: 1.02 (95%CI: 1.02 to 1.03) (Supplementary Table 9). This was similar in males, OR: 1.02 (95% CI: 1.01 to 1.02). Females, but not males, were less likely to have been prescribed Atorvastatin if they had more years of education; e.g. the OR for Atorvastatin prescription for 20 years of education versus 7 years of education was 0.92 in females (95% CI 0.83 to 1.01) and 1.02 in males (95% CI 0.94 to 1.11). There was little evidence of an interaction between QRISK3 score and educational attainment on statin type in females and males (P value for interaction in females = 0.4; P value for interaction in males = 0.9) (Supplementary Figure 6).

When analyses were replicated using eligible participants with linked primary care data using i) baseline measures of QRISK3 and self-report statin use, ii) baseline measures of QRISK3 with statin use validated by a prescription and iii) QRISK or QRISK2 score recorded in primary care data with a statin prescription, the evidence for interaction between QRISK3 and educational attainment on statin use remained in females (Figure 2 and Supplementary Figure 7). In males, the interaction between baseline QRISK3 scores and educational attainment on validated prescription remained. However, there was less evidence of an interaction between the primary care recorded QRISK scores and educational attainment on statin prescriptions (P=0.09), although the direction of effect was similar where males with 20 years of education were more likely to be prescribed statins (OR: 1.08; 95% CI: 1.07 to 1.10) than those with 7 years of education (OR: 1.05; 95% CI: 1.03 to 1.08) (Figure 2 and Supplementary Figure 7).

333 Figure 2: Odds of statin use recorded in primary care prescription data per unit increase in A)

334 baseline QRISK3 score and B) QRISK or QRISK2 score recorded in primary care, in females and males



335 *Analyses stratified by years of education provide an estimate of interaction on the multiplicative*
336 *scale*

337 *Baseline QRISK3: P value for interaction in females = <0.001 and males = <0.001*

338 *QRISK score recorded in primary care: P value for interaction in females = 0.034 and males = 0.091*

339 In the complete case sample, there was evidence of an interaction between QRISK3 and education in

340 both males and females considering reported statin use as the outcome, where the P value for

341 interaction was <0.001 for both females and males. However, there was little evidence of an

342 interaction between QRISK3 and education on statin type (Supplementary Table 10).

343 Pairwise correlation between the baseline derived QRISK3 score and QRISK3 scores derived

344 excluding i) systolic blood pressure variability estimated from the difference between two baseline

measures and ii) self-report of any CVD in a mother, father or sibling, were high (all >0.97) (Supplementary Table 11).

Discussion

Despite there being a higher prevalence of statin prescribing overall in those with lower levels of education, at a given level of QRISK3 score as a measure of clinical assessment of cardiovascular risk, less educated individuals were less likely to receive statin treatment compared to more highly educated individuals.

Results in context

Lifestyle and behavioural factors, such as BMI, diet, smoking, risky drinking and exercise have previously been implicated as mediators of the association between education and CVD (17, 18, 40-46). Indeed, the higher overall prevalence of statins in lower educated individuals is likely due to the greater prevalence of these intermediate risk factors, compared with those of greater education (5, 17, 44). However, much of the association between education and CVD remains unexplained. The results presented in this analysis suggest that access to preventative medication for CVD may be contributing to persisting socioeconomic inequalities.

It has previously been reported that inequalities exist in favour of those with higher SEP when accessing preventative healthcare (47). In the UK, National Health Service (NHS) health checks are offered to all residents aged between 40 and 74 without pre-existing conditions every 5 years, with the aim of preventing a number of diseases including CVD (such as by calculating QRISK scores), kidney disease and dementia (48). In a recent systematic review by Bunten and colleagues, seven studies were identified that indicated uptake of these health checks is lower in more socioeconomically deprived groups (49). Additionally one study included in this systematic review identified a trend towards lower uptake in smokers; an important risk factor for CVD that is also socially patterned (49, 50). Similar findings were also reported by Wilson and colleagues (51). These

369 reasons for non-uptake of health checks, in combination with the inequalities identified in this study,
370 indicate that methods to improve engagement with NHS health checks and preventative screening
371 methods may reduce inequalities in cardiovascular outcomes.

372 Indeed, differences in health seeking behaviours may be driving some of the inequalities in statin use
373 identified in our study. However, when interaction analyses were repeated using QRISK or QRISK2
374 scores recorded in primary care data and primary care records of statin prescriptions, these
375 inequalities remained. Therefore, attendance to primary care clinics cannot be the sole driver of
376 these inequalities.

377 The literature is mixed in the direction to which inequalities in access to statins exist, where some
378 studies suggest that individuals with lower socioeconomic position are less likely to be prescribed
379 statins (9, 10, 15, 16) and other studies finding the opposite or no differences (6, 8, 11, 13, 14). Of
380 these previous studies, there was limited consideration for underlying cardiovascular risk in the
381 analyses. Some studies adjusted for cardiovascular comorbidities (8, 13, 15, 16) such as cholesterol
382 level, diabetes status or prevalent cardiovascular events. However, we only identified one other
383 study that comprehensively adjusted for cardiovascular risk (11). Forde and colleagues established
384 risk status via 10-year absolute risk of coronary heart disease determined using the Framingham
385 study (11, 52) and assessed SEP by British civil service grade of employment. In contrast to our
386 results using educational attainment as a measure of SEP, they did not find evidence of inequalities
387 in statin use. The differences in our results compared with Forde and colleagues could be the
388 different measure of SEP used (income vs education) or due to cohort differences, where Forde and
389 colleagues used an occupational cohort study and here, we have used a population-based cohort.
390 Additionally, it has been demonstrated that the QRISK score has a greater predictive power
391 compared with the Framingham score (53). Therefore, our analyses may better account for
392 underlying differences in cardiovascular risk.

393 Currently, the QRISK3 scores capture the prevalence of key risk factors in individuals, such as BMI,
394 blood pressure and smoking, but our results show that accounting for these factors alone is not
395 enough to address cardiovascular inequalities. Cardiovascular risk scores may need to be adapted to
396 pay greater attention to SEP; something that has been described previously in the literature (54-56)
397 These risk scores should be in principle, easy to use and clear for clinicians, where it has previously
398 been reported that the use of risk scores in general practice is a source of confusion (57).

399 Despite there being almost 30 000 first instances of statin prescriptions after 1st January 2008
400 (where QRISK scores were first introduced in 2007), in the primary care data linked with UK Biobank,
401 there were only around 14 000 individuals with a recorded QRISK or QRISK2 scores in the same data.
402 This is higher than in previous research by Finnikin and colleagues, where they identified using
403 primary care records, that only 27% of patients prescribed statins had a recorded QRISK2 score (58).
404 However, the lack of recorded QRISK scores, suggests the decision to prescribe statin treatment may
405 be independent of an objective measure of cardiovascular risk, and potentially prescribed based on
406 more subjective measures by the clinician or the patient.

407 In individuals with linked primary care data, 14% of eligible participants reported using statins to
408 study nurses, however only 3% of participants had a linked prescription in the three months before
409 and after baseline. These individuals without a linked prescription are likely a combination of
410 individuals who are purchasing statins over the counter, have received a prescription from a private
411 clinician, or are no longer prescribed statins. The majority (91%) of those without a linked
412 prescription reported taking Simvastatin (currently the only statin available as an over the counter
413 medicine). Although we cannot definitively discern the reason these individuals did not have a
414 prescription, it is possible that accessing statins through non-NHS GPs (i.e. through private practices)
415 or over the counter is further contributing to inequalities in cardiovascular outcomes. There is, to
416 date, little freely available data on the prevalence of purchasing statins over the counter, rather than

417 via attending a primary care clinic. However, our data suggests it could indeed be highly prevalent in
418 the population.

419 ## Strengths and limitations

420 The major strength of our work is the large sample size and array of data available. Given the age
421 range of our participants (45-76 years) reported statin use is highly prevalent (10% in females and
422 17% in males). Additionally, the linked primary care data for 44% of the eligible sample allowed us to
423 i) validate self-reported statin use and ii) compare different mechanisms inequalities may be arising.
424 Where inequalities are present in primary care recorded QRISK scores, inequalities are unlikely to be
425 due to health seeking behaviour and more likely due to factors arising within clinic settings.
426 Conversely, where data is used from UK Biobank baselines assessment, inequalities may be due to
427 either differences in health seeking behaviour (i.e. attending NHS health checks) or factors that arise
428 within the healthcare setting.

429 Lifestyle and behavioural characteristics, which are incorporated in to the QRISK3 score, are likely to
430 be captured much more accurately and completely in UK Biobank compared with a primary care
431 setting. However, there may be some settings where UK Biobank variables may have been measured
432 differently than they would in primary care (59), such as non-fasting blood biomarker
433 measurements. However, the magnitude to which these measurements differ is unlikely to
434 introduce much bias to estimates of the QRISK3 score. Additionally, selection bias is present in UK
435 biobank, where participants are generally of a higher socioeconomic position and healthier than the
436 general population (60). Those who are of a lower socioeconomic position in the UK Biobank
437 potentially differ to those of an equivalent socioeconomic position (or level of educational
438 attainment) in the general population, where UK Biobank participants may be more health conscious
439 and health aware. Therefore, it is possible that the inequalities in the wider population are greater
440 than the inequalities reported here.

441 Despite our large sample size and wealth of data, a number of assumptions were made when
442 generating the QRISK3 scores. For example, in the QRISK3 algorithm (23), the study authors specify
443 medications should be considered if the individual has two or more prescriptions for each class of
444 medication (e.g. corticosteroid or atypical antipsychotic). We were not able to determine the
445 number of prescriptions at baseline and relied on a single self-report measure of medication use.
446 Therefore, medication use may be overestimated in our sample, which would result in an
447 overestimate of the QRISK3 score. Additionally, some measures, such as systolic blood pressure
448 variability and coronary heart disease in a first degree relative under the age of 60, are not available
449 in the UK Biobank data. Although we have included measures likely to capture some of these
450 variables, this may introduce bias to the QRISK3 estimate in UK Biobank compared with a primary
451 care setting.

452 The ISCED definitions of educational attainment (years in schooling) can differ with respect to other
453 measures of socioeconomic position. For example, using ISCED definitions, individuals who left
454 school with a vocational qualification are given a high number of years of schooling (19 years) but
455 will typically go into manual labour jobs. This is likely to explain some of the non-linearities in effects
456 stratified by educational attainment.

457 Clinical implications

458 The results presented here highlight inequalities in statin use by educational attainment. Given the
459 persisting inequalities in CVD, addressing the contribution of differences in statin prescription
460 provides a clear policy target. The two complimentary data sources used in this analysis, UK Biobank
461 baseline data and linked primary care data, indicate two potential mechanisms for these
462 inequalities. Firstly, there are likely to be differences in health seeking behaviour such as in attending
463 NHS health checks as previously evidenced in the literature. Secondly, the inequalities present in the
464 primary care data suggest there are important interactions between the healthcare practitioner and
465 patient that result in unequal prescribing of statins.

466 Healthcare professionals should consider potential biases in prescribing preventative treatments, or
467 in carrying out risk assessments, such as calculating a QRISK score. Additionally, patient preference
468 for treatment may be socially patterned (61). However, addressing these inequalities requires
469 systemic change and different interventions may be required to address the different mechanisms of
470 inequalities. For example, policy makers and healthcare professionals should consider how they can
471 improve the uptake of NHS health checks, where these risk assessments are carried out, in those
472 who are socioeconomically deprived.

473 Conclusions

474 Our analyses demonstrate that at a given level of cardiovascular risk, people with lower levels of
475 educational attainment are less likely to be prescribed statins than people with higher educational
476 attainment, meaning differences in statin prescribing likely contribute to inequalities in
477 cardiovascular disease. Policies should consider how these inequalities can be minimised.

References

1. Marmot MG, McDowall ME. Mortality decline and widening social inequalities. Lancet. 1986;2(8501):274-6.
2. Bajekal M, Scholes S, O'Flaherty M, Raine R, Norman P, Capewell S. Unequal trends in coronary heart disease mortality by socioeconomic circumstances, England 1982-2006: an analytical study. PLoS One. 2013;8(3):e59608.
3. Tillmann T, Vaucher J, Okbay A, Pikhart H, Peasey A, Kubinova R, et al. Education and coronary heart disease: mendelian randomisation study. BMJ. 2017;358:j3542.
4. Davies NM, Dickson M, Davey Smith G, van den Berg GJ, Windmeijer F. The causal effects of education on health outcomes in the UK Biobank. Nature Human Behaviour. 2018;2(2):117-25.
5. Carter AR, Gill D, Davies NM, Taylor AE, Tillmann T, Vaucher J, et al. Understanding the consequences of education inequality on cardiovascular disease: mendelian randomisation study. BMJ. 2019;365:l1855.
6. Fleetcroft R, Schofield P, Ashworth M. Variations in statin prescribing for primary cardiovascular disease prevention: cross-sectional analysis. BMC Health Serv Res. 2014;14:414.
7. O'Keeffe AG, Petersen I, Nazareth I. Initiation rates of statin therapy for the primary prevention of cardiovascular disease: an assessment of differences between countries of the UK and between regions within England. BMJ Open. 2015;5(3):e007207.
8. Simpson CR, Hannaford PC, Williams D. Evidence for inequalities in the management of coronary heart disease in Scotland. Heart. 2005;91(5):630-4.
9. Thomsen RW, Johnsen SP, Olesen AV, Mortensen JT, Boggild H, Olsen J, et al. Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol. 2005;60(5):534-42.
10. Packham C, Robinson J, Morris J, Richards C, Marks P, Gray D. Statin prescribing in Nottingham general practices: a cross-sectional study. J Public Health Med. 1999;21(1):60-4.
11. Forde I, Chandola T, Raine R, Marmot MG, Kivimaki M. Socioeconomic and ethnic differences in use of lipid-lowering drugs after deregulation of simvastatin in the UK: the Whitehall II prospective cohort study. Atherosclerosis. 2011;215(1):223-8.
12. Ramsay SE, Morris RW, Papacosta O, Lennon LT, Thomas MC, Whincup PH. Secondary prevention of coronary heart disease in older British men: extent of inequalities before and after implementation of the National Service Framework. J Public Health (Oxf). 2005;27(4):338-43.
13. Ashworth M, Lloyd D, Smith RS, Wagner A, Rowlands G. Social deprivation and statin prescribing: a cross-sectional analysis using data from the new UK general practitioner 'Quality and Outcomes Framework'. J Public Health (Oxf). 2007;29(1):40-7.
14. O'Keeffe AG, Nazareth I, Petersen I. Time trends in the prescription of statins for the primary prevention of cardiovascular disease in the United Kingdom: a cohort study using The Health Improvement Network primary care data. Clin Epidemiol. 2016;8:123-32.
15. Forsberg PO, Li X, Sundquist K. Neighborhood socioeconomic characteristics and statin medication in patients with myocardial infarction: a Swedish nationwide follow-up study. BMC Cardiovasc Disord. 2016;16(1):146.
16. Rasmussen JN, Gislason GH, Rasmussen S, Abildstrom SZ, Schramm TK, Kober L, et al. Use of statins and beta-blockers after acute myocardial infarction according to income and education. J Epidemiol Community Health. 2007;61(12):1091-7.
17. Mejean C, Droomers M, van der Schouw YT, Sluijs I, Czernichow S, Grobbee DE, et al. The contribution of diet and lifestyle to socioeconomic inequalities in cardiovascular morbidity and mortality. International Journal of Cardiology. 2013;168(6):5190-5.
18. Veronesi G, Ferrario MM, Kuulasmaa K, Bobak M, Chambless LE, Salomaa V, et al. Educational class inequalities in the incidence of coronary heart disease in Europe. Heart. 2016;102(12):958-65.

527 19. Mitchell AJ, Selmes T. Why don't patients attend their appointments? Maintaining
528 engagement with psychiatric services. Advances in Psychiatric Treatment. 2018;13(6):423-34.
529 20. Campbell K MA, McCartney G, McCullough S (NHS Health Scotland). Who is least likely to
530 attend? An analysis of outpatient appointment 'Did Not Attend' (DNA) data in Scotland. NHS Health
531 Scotland; 2015.
532 21. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and
533 validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective
534 open cohort study. BMJ. 2007;335(7611):136.
535 22. Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting
536 cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ.
537 2008;336(7659):1475-82.
538 23. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction
539 algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ.
540 2017;357:j2099.
541 24. Farnier M, Portal JJ, Maigret P. Efficacy of atorvastatin compared with simvastatin in patients
542 with hypercholesterolemia. J Cardiovasc Pharmacol Ther. 2000;5(1):27-32.
543 25. Insull W, Kafonek S, Goldner D, Zieve F. Comparison of efficacy and safety of atorvastatin
544 (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators. Am J Cardiol. 2001;87(5):554-9.
545 26. Karalis DG, Ross AM, Vacari RM, Zarren H, Scott R. Comparison of efficacy and safety of
546 atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.
547 Am J Cardiol. 2002;89(6):667-71.
548 27. Moon JC, Bogle RG. Switching statins. BMJ. 2006;332(7554):1344-5.
549 28. Biobank U. Hospital inpatient data.
550 https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/HospitalEpisodeStatistics.pdf; 2019 September
551 2019.
552 29. Biobank U. Primary Care Linked Data.
553 http://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/primary_care_data.pdf; 2019 September 2019.
554 30. NICE. Cardiovascular disease: risk assessment and reduction, including lipid modification.
555 www.nice.org.uk/guidance/cg1812014.
556 31. NICE. Cardiovascular risk assessment and lipid modification.
557 www.nice.org.uk/guidance/qs1002015.
558 32. Okbay A, Beauchamp JP, Fontana MA, Lee JJ, Pers TH, Rietveld CA, et al. Genome-wide
559 association study identifies 74 loci associated with educational attainment. Nature.
560 2016;533(7604):539-42.
561 33. NICE. Familial hypercholesterolaemia. https://www.nice.org.uk/guidance/qs412013.
562 34. NICE. Lipid modification - CVD prevention. https://cks.nice.org.uk/lipid-modification-cvd-
563 prevention2019.
564 35. Royston P. Multiple Imputation of Missing Values. The Stata Journal. 2004;4(3):227-41.
565 36. Spratt M, Carpenter J, Sterne JA, Carlin JB, Heron J, Henderson J, et al. Strategies for multiple
566 imputation in longitudinal studies. Am J Epidemiol. 2010;172(4):478-87.
567 37. Tilling K, Williamson EJ, Spratt M, Sterne JA, Carpenter JR. Appropriate inclusion of
568 interactions was needed to avoid bias in multiple imputation. J Clin Epidemiol. 2016;80:107-15.
569 38. Zhao M, Vaartjes I, Graham I, Grobbee D, Spiering W, Klipstein-Grobusch K, et al. Sex
570 differences in risk factor management of coronary heart disease across three regions. Heart.
571 2017;103(20):1587-94.
572 39. Millett ERC, Peters SAE, Woodward M. Sex differences in risk factors for myocardial
573 infarction: cohort study of UK Biobank participants. BMJ. 2018;363:k4247.
574 40. Hossin MZ, Koupil I, Falkstedt D. Early life socioeconomic position and mortality from
575 cardiovascular diseases: an application of causal mediation analysis in the Stockholm Public Health
576 Cohort. BMJ Open. 2019;9(6):e026258.

41. Havranek EP, Mujahid MS, Barr DA, Blair IV, Cohen MS, Cruz-Flores S, et al. Social Determinants of Risk and Outcomes for Cardiovascular Disease A Scientific Statement From the American Heart Association. Circulation. 2015;132(9):873-98.
42. Nordahl H, Rod NH, Frederiksen BL, Andersen I, Lange T, Diderichsen F, et al. Education and risk of coronary heart disease: assessment of mediation by behavioral risk factors using the additive hazards model. Eur J Epidemiol. 2013;28(2):149-57.
43. Degano IR, Marrugat J, Grau M, Salvador-Gonzalez B, Ramos R, Zamora A, et al. The association between education and cardiovascular disease incidence is mediated by hypertension, diabetes, and body mass index. Sci Rep. 2017;7(1):12370.
44. Kershaw KN, Droomers M, Robinson WR, Carnethon MR, Daviglus ML, Monique Verschuren WM. Quantifying the contributions of behavioral and biological risk factors to socioeconomic disparities in coronary heart disease incidence: the MORGEN study. Eur J Epidemiol. 2013;28(10):807-14.
45. van Oort FVA, van Lenthe FJ, Mackenbach JP. Material, psychosocial, and behavioural factors in the explanation of educational inequalities in mortality in the Netherlands. J Epidemiol Commun H. 2005;59(3):214-20.
46. Lynch JW, Kaplan GA, Cohen RD, Tuomilehto J, Salonen JT. Do cardiovascular risk factors explain the relation between socioeconomic status, risk of all-cause mortality, cardiovascular mortality, and acute myocardial infarction? American Journal of Epidemiology. 1996;144(10):934-42.
47. Cookson R, Propper C, Asaria M, Raine R. Socio-Economic Inequalities in Health Care in England. Fisc Stud. 2016;37(3-4):371-403.
48. England PH. Using the world leading NHS Health Check programme to prevent CVD https://www.gov.uk/government/publications/using-the-nhs-health-check-programme-to-prevent-cvd/using-the-world-leading-nhs-health-check-programme-to-prevent-cvd2018 [updated 24/01/2018. Available from: https://www.gov.uk/government/publications/using-the-nhs-health-check-programme-to-prevent-cvd/using-the-world-leading-nhs-health-check-programme-to-prevent-cvd.
49. Bunten A, Porter L, Gold N, Bogle V. A systematic review of factors influencing NHS health check uptake: invitation methods, patient characteristics, and the impact of interventions. BMC Public Health. 2020;20(1):93.
50. Dalton AR, Bottle A, Okoro C, Majeed A, Millett C. Uptake of the NHS Health Checks programme in a deprived, culturally diverse setting: cross-sectional study. J Public Health (Oxf). 2011;33(3):422-9.
51. Wilson R, Kuh D, Stafford M. Variations of health check attendance in later life: results from a British birth cohort study. BMC Public Health. 2019;19(1):1518.
52. D'Agostino RB, Sr., Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743-53.
53. Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ. 2009;339:b2584.
54. Brindle PM, McConnachie A, Upton MN, Hart CL, Davey Smith G, Watt GC. The accuracy of the Framingham risk-score in different socioeconomic groups: a prospective study. Br J Gen Pract. 2005;55(520):838-45.
55. Tunstall-Pedoe H, Woodward M, estimation Sgor. By neglecting deprivation, cardiovascular risk scoring will exacerbate social gradients in disease. Heart. 2006;92(3):307-10.
56. Woodward M, Brindle P, Tunstall-Pedoe H, estimation Sgor. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart. 2007;93(2):172-6.
57. Liew SM, Blacklock C, Hislop J, Glasziou P, Mant D. Cardiovascular risk scores: qualitative study of how primary care practitioners understand and use them. Br J Gen Pract. 2013;63(611):e401-7.

628 58. Finnikin S, Ryan R, Marshall T. Statin initiations and QRISK2 scoring in UK general practice: a
629 THIN database study. Br J Gen Pract. 2017;67(665):e881-e7.
630 59. Elliott P, Peakman TC, Biobank UK. The UK Biobank sample handling and storage protocol for
631 the collection, processing and archiving of human blood and urine. Int J Epidemiol. 2008;37(2):234-
632 44.
633 60. Fry A, Littlejohns TJ, Sudlow C, Doherty N, Adamska L, Sprosen T, et al. Comparison of
634 Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the
635 General Population. Am J Epidemiol. 2017;186(9):1026-34.
636 61. Schroder SL, Fink A, Richter M. Socioeconomic differences in experiences with treatment of
637 coronary heart disease: a qualitative study from the perspective of elderly patients. BMJ Open.
638 2018;8(11):e024151.

639